Navigation Links
Aethlon Medical Releases Shareholder Letter
Date:9/15/2009

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

    To our Shareholders:

    In advance of tomorrow's annual meeting, I wish to thank those
    shareholders who returned proxies supporting measures to re-elect our
    board of directors, reappoint our auditors, and increase the authorized
    shares of our common stock.  The results of your votes will be tabulated
    during our meeting and disclosed shortly thereafter.

    I would also like to take this opportunity to disclose that our
    manufacturing program with Bioserv/NextPharma Technologies is now
    underway, and that infectious disease researchers have provided initial
    verification that our Hemopurifier(R) is able to capture the emerging H1N1
    swine flu virus. We are additionally honored to reestablish a cooperative
    research and development agreement with the U.S. Army Medical Research
    Institute of Infectious Diseases (USAMRIID) that will continue our
    research into treating Ebola and other highly lethal pathogens.

    While I am pleased we have advanced these initiatives, our primary focus
    remains directed towards leveraging our therapeutic opportunity in
    Hepatitis-C care and establishing strategic relationships that will
    maximize long-term economic value for shareholders.  In this regard, we
    are actively pursuing relationships that offer to augment or
    significantly expand our clinical, distribution, and manufacturing
    capabilities.  However, I want to stress the complexity underlying any
    such relationship should not be underestimated.  We face issues that
    include competition between players in the medical device space, scaling
    of manufacturing at feasible costs, and developing appropriate
    distribution channels in a variety of markets.  Additionally, we maintain
    a firm stance that Aethlon Medical shareholders should maintain 100%
    ownership of our Hemopurifier(R) technology.  Regardless of these
    challenges, I am increasingly confident that we will establish
    relationships that provide us the foundation to transition our science
    into a successful business enterprise.

    On behalf of our dedicated team at Aethlon Medical, I thank you for your
    continued support and look forward to meeting those of you who attend
    tomorrow's meeting.

    Very truly yours,

    James A. Joyce
    Chairman, CEO

Certain of the statements within this shareholder letter may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the Company's ability to forge corporate partnerships on terms acceptable to the Company or at all, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

    Contacts:

    Jon Cunningham
    RedChip Companies Inc.
    (407) 644-4256
    (407) 491-4498 -cell
    Dave@redchip.com or Jon@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aethlon Medical to Present at Todays Southern California Investor Conference
2. Aethlon Medical Initiates Swine Flu Testing Program
3. Aethlon Medical Announces U.S. Army Agreement
4. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
5. Aethlon Medical Discloses New HIV/AIDS Treatment Data
6. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
7. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
8. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
9. Emergency Medical Transport By Air Carries Risks
10. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
11. Medical Doctor Creates Mantra Medicine Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit ... as the latest addition to its growing list of Partner Firms. S.S. ... Southeast, from Orlando to Huntsville and in between. , Harnessing the experience and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... it has been awarded the prestigious Distinguished Emerald Club of the World award, ... by BoardRoom magazine, one of the most respected trade publications serving private clubs. ...
(Date:2/10/2016)... Petaluma, CA (PRWEB) , ... February 10, 2016 , ... ... newest and most versatile series of monitor mounts ever. , “Our goal was ... flexible and easy to install system that we have ever created.” said Darren Hulsey, ...
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for Mid-South ... President Joe Wiley made the announcement Monday night, Feb. 8, prior to the evening ... of FHU and the creator of GO! Camp, has been named director. Gayle McDonald, ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced further details of three ... functional aspects of Lewy body dementia, a disease ... Two out of the three studies were recently ... later this quarter. In addition, the Company reported ...
(Date:2/9/2016)... Mass. , Feb. 9, 2016   AllCare ... The Joint Commission,s Gold Seal of Approval ® ... compliance with its performance standards. The Gold Seal of ... reflects an organization,s commitment to providing safe and effective ... AllCare Plus Pharmacy underwent a rigorous on-site survey ...
(Date:2/9/2016)... 9, 2016 The new report "Global Diagnostic Ultrasound Devices ... Consulting group reveals that global diagnostic ultrasound devices market was valued ... US$ 7,466.3 million by 2019 at a CAGR of 6.8% from ... ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
Breaking Medicine Technology: